Eman93
4,750 posts
msg #91824
- Ignore Eman93 |
4/30/2010 9:10:27 AM
BZH could be a trade today
|
karennma
8,057 posts
msg #91828
- Ignore karennma |
4/30/2010 10:00:42 AM
STEC on crash n' burn ..
|
karennma
8,057 posts
msg #91829
- Ignore karennma
modified |
4/30/2010 10:01:39 AM
STEC just bounced off $14.43
edit:
Still on crash n' burn = $13.86
edit:
up she goes 13.78 to 14.22
|
Eman93
4,750 posts
msg #91830
- Ignore Eman93 |
4/30/2010 10:05:16 AM
SDS trade working
|
Eman93
4,750 posts
msg #91831
- Ignore Eman93
modified |
4/30/2010 10:26:11 AM
I am going to try and let SDS thing work.... and not sell for a quick buck
in at 28.80
SDS stop loss set at 28.80 target is 31.50... a break of the inverse head and shoulders....neck line at 30
If we break the right shoulder at 28.80 this market will retest the highs and may double the pattern to the upside....
|
karennma
8,057 posts
msg #91836
- Ignore karennma |
4/30/2010 12:11:13 PM
OMG!
Look at 5-day DNDN chart!
|
johnpaulca
12,036 posts
msg #91839
- Ignore johnpaulca |
4/30/2010 12:47:34 PM
I have a friend who has 30000 sh DNDN at $5, he kept telling me to get some, I have very bad experiences with these Pharma stocks wouldn't take them for free.
|
Eman93
4,750 posts
msg #91840
- Ignore Eman93
modified |
4/30/2010 12:58:24 PM
I am such amateur an sold SDS at 29.60........
(no guts to hold for a swing)
|
Eman93
4,750 posts
msg #91841
- Ignore Eman93 |
4/30/2010 2:06:31 PM
I remember trading DNDN at the 3$ cross for a day trade....
look at RTK ........ thats a blast from the past.
|
Eman93
4,750 posts
msg #91877
- Ignore Eman93 |
4/30/2010 10:41:51 PM
I thought this interesting since we were talking about cancer drug lottery tickes:
This is good news for CYCC
4:34PM Cyclacel Pharma receives complaint filed by Celgene seeking to avoid certain cyclacel patents (CYCC) 2.30 -0.03 : Co announced that it received a complaint filed by Celgene Corporation (CELG) seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene's products and are invalid. Cyclacel and its counsel have not had an opportunity to thoroughly review these filings. The four patents cited in the complaint do not involve Cyclacel's clinical development candidates nor its commercial products.
|